Clinical Report: Innovative Device Targets Eye Pressure Without Surgery or Meds

Overview

The FYSX Ocular Pressure Adjusting Pump is the first FDA-approved nonpharmacological, nonsurgical treatment for lowering intraocular pressure (IOP) in glaucoma patients. Clinical studies demonstrated a mean IOP reduction of 39% in patients with low or normal eye pressure.

Background

Glaucoma management traditionally relies on pharmacological and surgical interventions to lower IOP, particularly in patients with normal-tension glaucoma, where treatment options are limited. The introduction of the FYSX device represents a significant advancement, offering a non-invasive alternative that can effectively reduce IOP without the complications associated with surgery or medication. This innovation is crucial for improving patient outcomes and expanding treatment options.

Data Highlights

Key Findings

• The FYSX device is the first FDA-approved nonpharmacological, nonsurgical treatment for glaucoma.
• It effectively lowers IOP in patients with low or normal eye pressure, achieving a mean reduction of 39%.
• The device utilizes negative pressure within goggles worn during sleep to create a microenvironment that reduces IOP.
• Patients reported minimal discomfort and adapted quickly to wearing the device at night.
• The FYSX system allows for personalized therapy by tracking usage and vacuum levels.
• It offers an alternative to traditional filtering procedures, which have inconsistent outcomes and safety concerns.

Clinical Implications

The FYSX Ocular Pressure Adjusting Pump provides a novel treatment option for glaucoma patients, particularly those with normal-tension glaucoma who may not respond well to conventional therapies. Clinicians can utilize this device to tailor IOP management strategies, potentially improving patient adherence and outcomes.

Conclusion

The introduction of the FYSX device marks a significant advancement in glaucoma treatment, offering a safe and effective means to lower IOP without the need for surgery or medication. Continued research and postmarketing studies will further elucidate its benefits in diverse patient populations.

References

1. Ophthalmic Devices Panel of the Medical Devices Advisory Committee Meeting, FDA, 2024 -- Evaluation of the FYSX Device
2. Swan RJ, Ferguson TJ, Shah M, et al., Transl Vis Sci Technol, 2020 -- Evaluation of the IOP-lowering effect of a multi-pressure dial
3. Samuelson TW, Ferguson TJ, Brubaker JW, et al., 2020 -- Negative pressure application to lower IOP in patients with suspected glaucoma
4. Glaucoma Physician — Product Spotlight: Microstent Uses Three-Prong Approach to Lower IOP
5. glaucoma physician — Innovative Goggles Offer Drug-free IOP Control
6. Ophthalmology Management — Spotlight on Technology & Technique
7. Ophthalmology Management — Quick Hits: Ophthalmology News From March 2024
8. Product Spotlight: Microstent Uses Three-Prong Approach to Lower IOP
9. Innovative Goggles Offer Drug-free IOP Control
10. Spotlight on Technology & Technique
11. FDA Grants DeNovo Classification for Treatment to Lower IOP
12. European Glaucoma Society – Terminology and guidelines for glaucoma, 6th Edition | British Journal of Ophthalmology
13. Circadian rhythm of intraocular pressure | The Journal of Physiological Sciences | Full Text